MARK2 and renal cell carcinoma: Linifanib, as an adenosine triphosphate competitive inhibitor, has a selective effect against VEGF receptors and platelet‐derived growth factor receptor tyrosine kinases but minimal activity against unrelated receptor tyrosine kinases, cytosolic tyrosine kinases and serine/threonine kinases in patients with advanced RCC [64].